Zobrazeno 1 - 10 of 197 pro vyhledávání: '"LaSala D"'
1
Akademický článek
Pharmacologic inhibition of dipeptidyl peptidase 1 (cathepsin C) does not block in vitro granzyme-mediated target cell killing by CD8 T or NK cells.
Autor: Sutton VR; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Watt SV; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Akhlaghi H; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Cipolla DC; Insmed Incorporated, Bridgewater, NJ, United States., Chen KJ; Insmed Incorporated, Bridgewater, NJ, United States., LaSala D; Insmed Incorporated, Bridgewater, NJ, United States., McDonald PP; Insmed Incorporated, Bridgewater, NJ, United States., Beavis PA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Munoz I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Hodel AW; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Noori T; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Voskoboinik I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia., Trapani JA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2024 Jul 03; Vol. 15, pp. 1396710. Date of Electronic Publication: 2024 Jul 03 (Print Publication: 2024).
Zobrazit plný text záznamu
2
Akademický článek
Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis.
Autor: McDonald PP; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Leifer FG; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Basso J; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Lasala D; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Li D; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Chen KJ; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Zhang J; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Perkins WR; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States., Cipolla DC; Department of Research, Insmed Incorporated, Bridgewater, NJ, United States.
Publikováno v: Frontiers in immunology [Front Immunol] 2023 Aug 11; Vol. 14, pp. 1231047. Date of Electronic Publication: 2023 Aug 11 (Print Publication: 2023).
Zobrazit plný text záznamu
3
Akademický článek
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
Autor: Basso J; Insmed Incorporated, Bridgewater, NJ, United States., Chen KJ; Insmed Incorporated, Bridgewater, NJ, United States., Zhou Y; Insmed Incorporated, Bridgewater, NJ, United States., Mark L; Insmed Incorporated, Bridgewater, NJ, United States., LaSala D; Insmed Incorporated, Bridgewater, NJ, United States., Dorfman A; Insmed Incorporated, Bridgewater, NJ, United States., Atalla M; Insmed Incorporated, Bridgewater, NJ, United States., Chun D; Insmed Incorporated, Bridgewater, NJ, United States., Viramontes V; Insmed Incorporated, Bridgewater, NJ, United States., Chang C; Insmed Incorporated, Bridgewater, NJ, United States., Leifer F; Insmed Incorporated, Bridgewater, NJ, United States., McDonald PP; Insmed Incorporated, Bridgewater, NJ, United States., Cipolla DC; Insmed Incorporated, Bridgewater, NJ, United States.
Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2023 Jul 19; Vol. 14, pp. 1208780. Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).
Zobrazit plný text záznamu
4
Akademický článek
Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice.
Autor: Chen KJ; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Zhang J; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., LaSala D; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Basso J; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Chun D; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Zhou Y; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., McDonald PP; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Perkins WR; Research Department of Insmed Incorporated, Bridgewater, NJ, United States., Cipolla DC; Research Department of Insmed Incorporated, Bridgewater, NJ, United States.
Publikováno v: Frontiers in immunology [Front Immunol] 2023 Jun 27; Vol. 14, pp. 1185727. Date of Electronic Publication: 2023 Jun 27 (Print Publication: 2023).
Zobrazit plný text záznamu
5
Akademický článek
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Autor: Cipolla D; Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA. david.cipolla@insmed.com., Zhang J; Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA., Korkmaz B; INSERM UMR-1100, 'Research Center for Respiratory Diseases' and University of Tours, Tours, France., Chalmers JD; Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK., Basso J; Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA., Lasala D; Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA., Fernandez C; Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA., Teper A; Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA., Mange KC; Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA., Perkins WR; Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA., Sullivan EJ; Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA.
Publikováno v: Respiratory research [Respir Res] 2023 May 17; Vol. 24 (1), pp. 133. Date of Electronic Publication: 2023 May 17.
Zobrazit plný text záznamu
8
Akademický článek
An optimized method of extracting and quantifying active Neutrophil serine proteases from human whole blood cells.
Autor: Basso J; Insmed Incorporated, Bridgewater, New Jersey, United States of America., Zhang J; Insmed Incorporated, Bridgewater, New Jersey, United States of America., Lasala D; Insmed Incorporated, Bridgewater, New Jersey, United States of America., Rose SJ; Insmed Incorporated, Bridgewater, New Jersey, United States of America., Chen KJ; Insmed Incorporated, Bridgewater, New Jersey, United States of America., Cipolla D; Insmed Incorporated, Bridgewater, New Jersey, United States of America.
Publikováno v: PloS one [PLoS One] 2022 Aug 31; Vol. 17 (8), pp. e0272575. Date of Electronic Publication: 2022 Aug 31 (Print Publication: 2022).
Zobrazit plný text záznamu
9
Akademický článek
Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections.
Autor: Plaunt AJ; Insmed Incorporated, Bridgewater, New Jersey, USA., Rose SJ; Insmed Incorporated, Bridgewater, New Jersey, USA., Kang JY; Insmed Incorporated, Bridgewater, New Jersey, USA., Chen KJ; Insmed Incorporated, Bridgewater, New Jersey, USA., LaSala D; Insmed Incorporated, Bridgewater, New Jersey, USA., Heckler RP; Insmed Incorporated, Bridgewater, New Jersey, USA., Dorfman A; Insmed Incorporated, Bridgewater, New Jersey, USA., Smith BT; Insmed Incorporated, Bridgewater, New Jersey, USA., Chun D; Insmed Incorporated, Bridgewater, New Jersey, USA., Viramontes V; Insmed Incorporated, Bridgewater, New Jersey, USA., Macaluso A; Insmed Incorporated, Bridgewater, New Jersey, USA., Li Z; Insmed Incorporated, Bridgewater, New Jersey, USA., Zhou Y; Insmed Incorporated, Bridgewater, New Jersey, USA., Mark L; Insmed Incorporated, Bridgewater, New Jersey, USA., Basso J; Insmed Incorporated, Bridgewater, New Jersey, USA., Leifer FG; Insmed Incorporated, Bridgewater, New Jersey, USA., Corboz MR; Insmed Incorporated, Bridgewater, New Jersey, USA., Chapman RW; Insmed Incorporated, Bridgewater, New Jersey, USA., Cipolla D; Insmed Incorporated, Bridgewater, New Jersey, USA., Perkins WR; Insmed Incorporated, Bridgewater, New Jersey, USA., Malinin VS; Insmed Incorporated, Bridgewater, New Jersey, USA., Konicek DM; Insmed Incorporated, Bridgewater, New Jersey, USA.
Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2021 Jun 17; Vol. 65 (7), pp. e0031621. Date of Electronic Publication: 2021 Jun 17.
Zobrazit plný text záznamu
10
Akademický článek
What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?
Autor: Moua, Teng1 (AUTHOR) baqir.misbah@mayo.edu, Baqir, Misbah1 (AUTHOR), Ryu, Jay H.1 (AUTHOR)
Publikováno v: Journal of Clinical Medicine. Nov2024, Vol. 13 Issue 21, p6304. 19p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje